PDCD1 and melanoma: In a cohort of advanced melanoma patients that received neoadjuvant Pembrolizumab before resection, anti-PD-1 therapy provoked an increase in CD8 TILs and an upregulation of PD-L1 and other genes involved in T cell activation and migration.